Published in Antimicrob Agents Chemother on February 01, 2001
New model of oropharyngeal candidiasis in mice. Antimicrob Agents Chemother (2001) 1.93
Development and validation of an in vivo Candida albicans biofilm denture model. Infect Immun (2010) 1.56
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother (2006) 1.55
Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis (2004) 1.23
Tissue penetration of antifungal agents. Clin Microbiol Rev (2014) 1.13
Comparison of echinocandin antifungals. Ther Clin Risk Manag (2007) 0.99
Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther (2011) 0.98
Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med (2014) 0.85
Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. Antimicrob Agents Chemother (2004) 0.84
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis (2011) 0.82
Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization. Antimicrob Agents Chemother (2013) 0.81
Efficacy of CS-758, a novel triazole, against experimental fluconazole-resistant oropharyngeal candidiasis in mice. Antimicrob Agents Chemother (2003) 0.77
Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev (2006) 0.75
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci (1988) 3.49
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 3.02
Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn Microbiol Infect Dis (1997) 2.70
In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob Agents Chemother (1997) 2.60
Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol (1997) 2.58
Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol (1994) 2.58
Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J Clin Microbiol (1987) 2.02
In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother (1997) 2.00
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00
Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic. Ann N Y Acad Sci (1988) 1.75
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother (1994) 1.61
Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob Agents Chemother (1998) 1.60
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother (1999) 1.60
A new therapeutic approach to Candida infections. A preliminary report. Arch Intern Med (1972) 1.42
Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob Agents Chemother (1991) 1.41
Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits. Antimicrob Agents Chemother (1990) 1.35
Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin Microbiol (2000) 1.32
The fungal cell wall as a drug target. Trends Microbiol (1995) 1.30
Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr (1992) 1.22
Etiology of esophageal disease in human immunodeficiency virus-infected patients who fail antifungal therapy. Am J Med (1996) 1.20
High-performance liquid chromatographic determination of amphotericin B in human serum. J Chromatogr (1987) 1.15
Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J Med Chem (1995) 1.08
In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species. Antimicrob Agents Chemother (1997) 1.04
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother (1999) 1.01
Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits. Antimicrob Agents Chemother (2000) 0.96
Histopathologic and immunohistochemical changes in gut-associated lymphoid tissues after treatment of rabbits with dexamethasone. Lab Invest (1992) 0.95
Determination of fluconazole in human serum by solid-phase extraction and reversed-phase high-performance liquid chromatography. Ther Drug Monit (1992) 0.89
Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother (1995) 0.87
Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Gastroenterology (1996) 0.86
Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factors. Pediatr Infect Dis J (2000) 0.81
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci (1988) 3.49
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Indinavir concentrations and St John's wort. Lancet (2000) 3.04
Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother (1996) 3.03
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol (2008) 2.95
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis (1996) 2.72
Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother (2001) 2.68
Human mycoses: drugs and targets for emerging pathogens. Science (1994) 2.52
Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol (1995) 2.51
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect (2014) 2.47
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol (2005) 2.29
Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis (1999) 2.28
The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol (2005) 2.21
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother (2001) 2.13
Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) (1986) 2.11
Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 2.11
Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis (2000) 2.09
Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol (1998) 2.09
Developments in hyalohyphomycosis and phaeohyphomycosis. J Med Vet Mycol (1994) 2.07
Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis (1994) 2.04
Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J Clin Microbiol (1987) 2.02
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol (2009) 1.99
Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis (1988) 1.95
Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 1.95
Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs (1992) 1.93
Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect (2001) 1.91
Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis (2001) 1.86
Neurotoxic effects of cisplatin therapy. Arch Neurol (1982) 1.83
PCR and single-strand conformational polymorphism for recognition of medically important opportunistic fungi. J Clin Microbiol (1995) 1.73
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 1.72
Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy (1995) 1.72
Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis (1992) 1.71
Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis (1991) 1.70
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect (2014) 1.70
Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun (1989) 1.67
Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J (1996) 1.66
Distinction of deep versus superficial clinical and nonclinical isolates of Trichosporon beigelii by isoenzymes and restriction fragment length polymorphisms of rDNA generated by polymerase chain reaction. J Clin Microbiol (1991) 1.66
New targets and delivery systems for antifungal therapy. Med Mycol (2000) 1.65
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother (1994) 1.61
Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis (2010) 1.60
Rapid extraction of genomic DNA from medically important yeasts and filamentous fungi by high-speed cell disruption. J Clin Microbiol (1998) 1.60
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother (1999) 1.60
Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis (1997) 1.59
Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest (1998) 1.58
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med (1995) 1.55
The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr (1991) 1.51
Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs (2001) 1.48
Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother (1995) 1.48
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother (1999) 1.48
Ictal scalp EEG in unilateral mesial temporal lobe epilepsy. Epilepsia (1998) 1.46
Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol (1985) 1.45
Infections due to Xylohypha bantiana (Cladosporium trichoides). Rev Infect Dis (1989) 1.45
The functional organization of the interictal spike complex in benign rolandic epilepsy. Epilepsia (1996) 1.45
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother (2001) 1.45
In vivo bypass of hemophilia A coagulation defect by factor XIIa implant. Nat Biotechnol (2000) 1.45
Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother (2001) 1.45